An Expert Perspective on Phosphate Dysregulation With a Focus on Chronic Hypophosphatemia

J Bone Miner Res. 2022 Jan;37(1):12-20. doi: 10.1002/jbmr.4486. Epub 2021 Dec 23.

Abstract

Because of their rarity, diseases characterized by chronic hypophosphatemia can be underrecognized and suboptimally managed, resulting in poor clinical outcomes. Moreover, serum phosphate may not be measured routinely in primary care practice. Authors participated in several working sessions to advance the understanding of phosphate homeostasis and the causes, consequences, and clinical implications of chronic hypophosphatemia. Phosphate levels are regulated from birth to adulthood. Dysregulation of phosphate homeostasis can result in hypophosphatemia, which becomes chronic if phosphate levels cannot be normalized. Chronic hypophosphatemia may be underrecognized as serum phosphate measurement is not always part of routine analysis in the primary care setting and results might be misinterpreted, for instance, due to age-specific differences not being accounted for and circadian variations. Clinical consequences of chronic hypophosphatemia involve disordered endocrine regulation, affect multiple organ systems, and vary depending on patient age and the underlying disorder. Signs and symptoms of chronic hypophosphatemic diseases that manifest during childhood or adolescence persist into adulthood if the disease is inadequately managed, resulting in an accumulation of clinical deficits and a progressive, debilitating impact on quality of life. Early identification and diagnosis of patients with chronic hypophosphatemia is crucial, and clinical management should be started as soon as possible to maximize the likelihood of improving health outcomes. Furthermore, in the absence of a universally accepted description for "chronic hypophosphatemia," a definition is proposed here that aims to raise awareness of these diseases, facilitate diagnosis, and guide optimal phosphate management strategies by improving monitoring and assessment of patient response to treatment. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Keywords: HYPOPHOSPHATEMIA; OSTEOMALACIA AND RICKETS; PARATHYROID HORMONE/VITAMIN D/FIBROBLAST GROWTH FACTOR 23; PHOSPHATE HOMEOSTASIS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Familial Hypophosphatemic Rickets* / drug therapy
  • Fibroblast Growth Factors / therapeutic use
  • Humans
  • Hypophosphatemia*
  • Osteomalacia* / drug therapy
  • Phosphates
  • Quality of Life

Substances

  • Phosphates
  • Fibroblast Growth Factors